Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation.
about
A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish.Cerebral Small Vessel Disease: Targeting Oxidative Stress as a Novel Therapeutic Strategy?Pharmacology and Clinical Drug Candidates in Redox MedicineNADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTSNADPH oxidase in stroke and cerebrovascular diseaseEvolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target EngagementNeuroprotection after stroke by targeting NOX4 as a source of oxidative stressTargeting NADPH oxidases in vascular pharmacologyPathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2NADPH oxidase as a therapeutic target for oxalate induced injury in kidneysDecreasing mitochondrial fission diminishes vascular smooth muscle cell migration and ameliorates intimal hyperplasia.Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegenerationOleoyl-lysophosphatidylcholine limits endothelial nitric oxide bioavailability by induction of reactive oxygen speciesNADPH oxidases: key modulators in aging and age-related cardiovascular diseases?Targeting Mitochondria and Reactive Oxygen Species-Driven Pathogenesis in Diabetic NephropathyBridged tetrahydroisoquinolines as selective NADPH oxidase 2 (Nox2) inhibitorsArterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGFTks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formationAtorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling.NADPH oxidases in vascular pathology.The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfallsRedox signaling, vascular function, and hypertension.Redox control of vascular smooth muscle migration.Vascular characterization of mice with endothelial expression of cytochrome P450 4F2.Ncf1 (p47phox) is essential for direct regulatory T cell mediated suppression of CD4+ effector T cells.Reactive oxygen species are involved in regulating alpha1-adrenoceptor-activated vascular smooth muscle contraction.Hypoxia-inducible factor-1 activation in nonhypoxic conditions: the essential role of mitochondrial-derived reactive oxygen species.Comparative pharmacology of chemically distinct NADPH oxidase inhibitors.The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferationNADPH oxidase-2 inhibition restores contractility and intracellular calcium handling and reduces arrhythmogenicity in dystrophic cardiomyopathy.Updates of reactive oxygen species in melanoma etiology and progression.Redox-based therapeutics in neurodegenerative disease.NOX1, 2, 4, 5: counting out oxidative stress.Smooth muscle specific overexpression of p22phox potentiates carotid artery wall thickening in response to injury.Mechanistic target of rapamycin complex 1 signaling regulates cell proliferation, cell survival, and differentiation in regenerating zebrafish fins.Emergency granulopoiesis promotes neutrophil-dendritic cell encounters that prevent mouse lung allograft acceptance.Lipopolysaccharide induces inducible nitric oxide synthase-dependent podocyte dysfunction via a hypoxia-inducible factor 1α and cell division control protein 42 and Ras-related C3 botulinum toxin substrate 1 pathway.Redox signaling at invasive microdomains in cancer cells.Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule InhibitorsRole of reactive oxygen and nitrogen species in the vascular responses to inflammation.
P2860
Q24649479-3761E29E-5502-46FC-AF95-29DBDBD7354BQ26751153-7C17104F-008D-4C3C-ADB9-66056BEF9AA0Q26785525-4A405A9F-8CA5-41FF-A604-297FA23A5580Q26821775-F3AB07D1-B1BA-4319-8CBE-984F2CA92312Q26859140-85BB6C36-9DE9-4D50-8429-7CA64545AEFEQ26861119-BC7F59BD-0265-4601-96E2-364F7CE6DD53Q26862779-6998B065-AE47-4628-8FAB-528425929071Q26863500-D017A545-2FC8-4C71-B8B0-13E491F04649Q27005956-46D3AD51-7719-42AC-8BCC-A443F585D68AQ27014373-59ACD8F9-C2DC-49AF-93F4-12C70D527433Q27302132-85B51EDF-6ED7-40BB-8899-E095CFF548A6Q27323209-170E22C8-034D-48E8-A725-41A6A8367536Q27324083-B633686B-2F57-44EF-847A-246A4A2E42C4Q28072348-BB796A9D-0F12-4745-A7A3-58CECD0952C7Q28083205-31E9043E-C052-4402-A661-570210413A96Q28394560-921526AC-4B67-4CFF-A7CC-7CCD6CCFEC45Q28582555-EBCE3B02-9A08-4191-AD15-88DA1B924EC1Q28586447-73AC866E-A50E-4A3D-8F92-03604913A0E1Q33555656-19F715F0-A9EF-42FF-B18B-DDD134814CE0Q33632089-419FDCD0-1F58-4A38-969A-0FA6E13F6F43Q33632757-83B9F192-2FF9-41A7-B2CA-67370389FA02Q33689229-4F2DCCBD-E6DB-4670-8437-58100C4E163FQ33690103-B58674C1-460E-4004-83EC-FC8C84DC77ABQ33775129-6C6ACAA4-4713-42F2-A6A2-5DCFE61A126DQ33799283-193682BC-6E03-4010-A9CB-EFA5B7A2B56BQ34097787-1C563346-323A-4963-89BB-A0D66BC59D36Q34123420-AF507AD1-499D-4414-8655-71AA9C6546BAQ34269250-899CBA6B-F23F-4941-9D1A-95DB779FFEDBQ34294854-95A2A24C-A3ED-40D2-97FC-47CFDB564E53Q34296737-0771043A-E95E-4106-AE8E-F74FFB512946Q34403921-B1169E33-DCA1-45C9-9CC0-079610DB23D9Q34535918-31A3D9B7-B4D9-46FC-9BB2-959BDB1E0695Q35375986-85AFA6BA-98DC-4498-B87F-9EE0895D4DFEQ35471157-23A4D889-104E-4280-A478-D33F01B7BBA0Q35495494-F09942B4-1C2E-4976-8581-80B2DC4F8C72Q35604072-4776194E-8730-4362-AC88-397E4743D5D2Q35688862-39DE05FD-9FB4-42D7-B0CE-D04E9F76A35BQ35738096-ADF6F633-9B95-48FC-B79D-964D911E1618Q35824748-87237A7F-30B4-47DC-B824-742AD9A96D4BQ35948515-4764B694-35EB-4145-840B-A009AFCE9A04
P2860
Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Novel Nox inhibitor VAS2870 at ...... otaxis, but not proliferation.
@en
Novel Nox inhibitor VAS2870 at ...... otaxis, but not proliferation.
@nl
type
label
Novel Nox inhibitor VAS2870 at ...... otaxis, but not proliferation.
@en
Novel Nox inhibitor VAS2870 at ...... otaxis, but not proliferation.
@nl
prefLabel
Novel Nox inhibitor VAS2870 at ...... otaxis, but not proliferation.
@en
Novel Nox inhibitor VAS2870 at ...... otaxis, but not proliferation.
@nl
P2093
P1476
Novel Nox inhibitor VAS2870 at ...... otaxis, but not proliferation.
@en
P2093
Anselm T Bäumer
Heinrich Sauer
Henrik ten Freyhaus
Jessika Schnitker
Kirstin Wingler
Maria Wartenberg
Marius Vantler
Michael Huntgeburth
Stephan Rosenkranz
P304
P356
10.1016/J.CARDIORES.2006.01.022
P577
2006-03-20T00:00:00Z